Free Trial

B. Riley Estimates Novavax's Q1 Earnings (NASDAQ:NVAX)

Novavax logo with Medical background
Remove Ads

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Equities research analysts at B. Riley dropped their Q1 2025 earnings per share estimates for Novavax in a research note issued on Monday, March 3rd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter, down from their prior forecast of ($0.38). The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. B. Riley also issued estimates for Novavax's Q2 2025 earnings at $0.64 EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at $0.11 EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.36 EPS.

NVAX has been the topic of a number of other reports. BTIG Research began coverage on Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. Finally, TD Cowen raised shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $18.00.

Get Our Latest Analysis on NVAX

Novavax Price Performance

NVAX traded up $0.47 on Wednesday, reaching $8.34. The company's stock had a trading volume of 5,070,652 shares, compared to its average volume of 8,084,745. Novavax has a 1 year low of $3.81 and a 1 year high of $23.86. The business's 50 day moving average is $8.46 and its 200 day moving average is $9.79. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -3.69, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92.

Remove Ads

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the prior year, the firm earned ($1.44) EPS.

Insider Activity

In other Novavax news, Director James F. Young sold 5,400 shares of Novavax stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rachel K. King sold 4,150 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now directly owns 14,770 shares of the company's stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 14,150 shares of company stock valued at $119,641. Company insiders own 1.00% of the company's stock.

Hedge Funds Weigh In On Novavax

Institutional investors have recently modified their holdings of the company. Creative Planning grew its position in Novavax by 34.5% in the 3rd quarter. Creative Planning now owns 32,482 shares of the biopharmaceutical company's stock worth $410,000 after purchasing an additional 8,339 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 1,598 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Novavax in the 3rd quarter worth approximately $214,000. Nisa Investment Advisors LLC increased its position in Novavax by 1,192.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 23,449 shares of the biopharmaceutical company's stock valued at $296,000 after acquiring an additional 21,635 shares during the period. Finally, US Bancorp DE boosted its position in Novavax by 3,538.8% during the 3rd quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock worth $155,000 after acquiring an additional 11,961 shares during the period. Institutional investors own 53.04% of the company's stock.

About Novavax

(Get Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Featured Stories

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Should You Invest $1,000 in Novavax Right Now?

Before you consider Novavax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.

While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

Flying cars are coming sooner than you think! Investors are getting excited about this futuristic industry, and MarketBeat analyst Chris Markoch breaks down 7 flying car stocks poised to take off.

Related Videos

Archer Aviation: Sinking Now, Soaring Soon?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Palantir’s Explosive Growth: Buy Now or Wait for a Dip?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads